Browse > Article
http://dx.doi.org/10.4110/in.2009.9.4.122

Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-$\beta$  

Park, Hae-Young (Laboratory of Immunology, Lee Gil-Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science)
Wakefield, Lalage M (Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health)
Mamura, Mizuko (Laboratory of Immunology, Lee Gil-Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science)
Publication Information
IMMUNE NETWORK / v.9, no.4, 2009 , pp. 122-126 More about this Journal
Abstract
Transforming growth factor-$\beta$ (TGF-$\beta$) is a highly pleiotropic cytokine playing pivotal roles in immune regulation. TGF-$\beta$ facilitates tumor cell survival and metastasis by targeting multiple cellular components. Focusing on its immunosuppressive functions, TGF-$\beta$ antagonists have been employed for cancer treatment to enhance tumor immunity. TGF-$\beta$ antagonists exert anti-tumor effects through #1 activating effector cells such as NK cells and cytotoxic $CD8^+$ Tcells (CTLs), #2 inhibiting regulatory/suppressor cell populations, #3 making tumor cells visible to immune cells, #4 inhibiting the production of tumor growth factors. This review focuses on the effect of TGF-$\beta$ on T cells, which are differentiated into effector T cells or newly identified tumor-supporting T cells.
Keywords
transforming growth factor-$\beta$ (TGF-$\beta$); primary tumor; metastasis; $CD8^＋$T cells; IL-17;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB: Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc Natl Acad Sci U S A 90;9944-9948, 1993   DOI   ScienceOn
2 Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM: Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68;3915-3923, 2008   DOI   ScienceOn
3 Martin-Orozco N, Dong C: The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 10;543-549, 2009   PUBMED
4 Bierie B, Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6;506-520, 2006   DOI   ScienceOn
5 McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ: The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10;314-324, 2009   DOI   ScienceOn
6 Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24;179-189, 2006   DOI   ScienceOn
7 Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109;1607-1615, 2002   DOI   PUBMED
8 Kapp JA, Bucy RP: CD8+ suppressor T cells resurrected. Hum Immunol 69;715-720, 2008   DOI   ScienceOn
9 Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M,Homma I, Sekikawa K, Asano M, Iwakura Y: Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17;375-387, 2002
10 Yamaguchi T, Sakaguchi S: Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16;115-123, 2006   DOI   ScienceOn
11 Miyazono K, Kusanagi K, Inoue H: Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187;265-276, 2001   DOI   ScienceOn
12 Humphrey LJ, Singla O, Volenec FJ: Immunologic responsiveness of the breast cancer patient. Cancer 46;893-898, 1980   DOI   PUBMED   ScienceOn
13 Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172;7335-7340, 2004   DOI   PUBMED
14 Roberts AB, Wakefield LM: The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 100;8621-8623, 2003   DOI   ScienceOn
15 Wrzesinski SH, Wan YY, Flavell RA: Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 13;5262-5270, 2007   DOI   ScienceOn
16 Thomas DA, Massagu\acute{e} J: TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8;369-380, 2005   DOI   ScienceOn
17 Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood 101;2620-2627, 2003   DOI   ScienceOn
18 Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206;1457-1464, 2009   DOI   ScienceOn
19 Alleva DG, Burger CJ, Elgert KD: Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 153;1674-1686, 1994   PUBMED
20 Yang L, Moses HL: Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 68;9107-9111, 2008   DOI   ScienceOn
21 Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24;99-146, 2006   DOI   ScienceOn
22 Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Toi M, Date H: Clinical features of surgical resection for pulmonary metastasis from breast cancer. Eur J Surg Oncol 35;393-397, 2009   DOI   PUBMED   ScienceOn
23 Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 454;436-444, 2008   DOI   ScienceOn
24 Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE: Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18;159-170, 2007   DOI   ScienceOn
25 Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF: Generation and regulation of human CD4＋ IL-17- producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 105;15505-15510, 2008   DOI   ScienceOn
26 Kryczek I, Wei S, Szeliga W, Vatan L, Zou W: Endogenous IL-17 contributes to reduced tumor growth and metastasis.Blood 114;357-359, 2009   DOI   ScienceOn
27 Ljunggren HG, K\ddot{a}rre K: In search of the ‘missing self: MHC molecules and NK cell recognition. Immunol Today 11; 237-244, 1990   DOI   ScienceOn
28 Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM: An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68;3835-3843, 2008   DOI   ScienceOn
29 Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15;114-123, 2009   DOI   ScienceOn
30 Kitamura T, Kometani K, Hashida H, Matsunaga A, Miyoshi H, Hosogi H, Aoki M, Oshima M, Hattori M, Takabayashi A, Minato N, Taketo MM: SMAD4-deficient intestinal tumors recruit CCR1＋ myeloid cells that promote invasion. Nat Genet 39;467-475, 2007   DOI   ScienceOn
31 Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M: Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 12;4315-4330, 2006   DOI   ScienceOn
32 Denoix PF: Enquete permanent dans les centres anticancereaux. Bull Inst Nat Hyg 1;70-75, 1946
33 Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L: Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202;919-929, 2005   DOI   ScienceOn